Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helle Linnebjerg

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Diabetes, Obesity & Metabolism|August 4, 2016
Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitusHelle Linnebjerg, Eric Chen Quin Lam, Xin Zhang, et al.
Diabetes, Obesity & Metabolism|January 10, 2018
Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitusNiels K Porksen, Helle Linnebjerg, Eric Chen Quin Lam, et al.
Journal of Diabetes|January 22, 2013
Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitusYi Min Cui, Xiao Hui Guo, Dong Mei Zhang, et al.
Clinical Pharmacology in Drug Development|August 19, 2021
A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese SubjectsHui Liu, Feng Wang, Yongjia Ji, et al.
Clinical Therapeutics|September 9, 2020
Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy SubjectsJennifer Leohr, Mary Anne Dellva, Elizabeth LaBell, et al.
Diabetes, Obesity & Metabolism|August 18, 2017
Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetesRakel F Johansen, Esben Søndergaard, Helle Linnebjerg, et al.
Clinical Pharmacology in Drug Development|September 24, 2017
LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose LevelsXin Zhang, Eric Chen Quin Lam, Mary E Seger, et al.
Regulatory Peptides|August 5, 2008
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetesHelle Linnebjerg, Soomin Park, Prajakti A Kothare, et al.
Diabetes, Obesity & Metabolism|March 28, 2023
Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitusRonnie Aronson, Torben Biester, Jennifer Leohr, et al.
Journal of Diabetes Science and Technology|February 21, 2015
Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese SubjectsAmparo de la Peña, Kwee P Yeo, Helle Linnebjerg, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Diabetes, Obesity & Metabolism|August 4, 2016
Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitusHelle Linnebjerg, Eric Chen Quin Lam, Xin Zhang, et al.
Diabetes, Obesity & Metabolism|January 10, 2018
Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitusNiels K Porksen, Helle Linnebjerg, Eric Chen Quin Lam, et al.
Journal of Diabetes|January 22, 2013
Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitusYi Min Cui, Xiao Hui Guo, Dong Mei Zhang, et al.
Clinical Pharmacology in Drug Development|August 19, 2021
A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese SubjectsHui Liu, Feng Wang, Yongjia Ji, et al.
Clinical Therapeutics|September 9, 2020
Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy SubjectsJennifer Leohr, Mary Anne Dellva, Elizabeth LaBell, et al.
Diabetes, Obesity & Metabolism|August 18, 2017
Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetesRakel F Johansen, Esben Søndergaard, Helle Linnebjerg, et al.
Clinical Pharmacology in Drug Development|September 24, 2017
LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose LevelsXin Zhang, Eric Chen Quin Lam, Mary E Seger, et al.
Regulatory Peptides|August 5, 2008
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetesHelle Linnebjerg, Soomin Park, Prajakti A Kothare, et al.
Diabetes, Obesity & Metabolism|March 28, 2023
Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitusRonnie Aronson, Torben Biester, Jennifer Leohr, et al.
Journal of Diabetes Science and Technology|February 21, 2015
Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese SubjectsAmparo de la Peña, Kwee P Yeo, Helle Linnebjerg, et al.
Pageof 4